Official Title: “A Comparative Study of Lansoprazole and Mosapride for Functional Dyspepsia: Focus on Difference Between Epigastric Pain Syndrome and Postprandial Distress Syndrome”

Functional dyspepsia is a common symptom complex with significant impact on quality of life.

There is no standard treatment for functional dyspepsia but therapeutic efficacy of proton pump inhibitor (PPI) and prokinetic agent have been proved in subsets of patients. This study has two aims: first is to compare the therapeutic efficacy of lansoprazole (a PPI) and mosapride (a prokinetic agent) for functional dyspepsia, and second is to investigate whether different subgroups of functional dyspepsia (e.g. epigastric pain syndrome and postprandial distress syndrome) respond differently to PPI and prokinetic agent.

Study Type: Interventional

Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study

Study Primary Completion Date: May 2009

Eligible outpatients with presentation of dyspepsia are enrolled if they fulfilled the criteria of ROME III criteria. A trained assistant helps the eligible patients to complete the ROME III standard questionaire, brief symptom rating scale (BSRS), and Maudsley Personality Inventory (MPI). The enrolled patients are then randomized into either lansoprazole or mosapride group for 14-day treatment. Before starting medication, right after completing the medication, and 1 month after the medication, the enrolled patients complete standardized severity questionnaire (Hong-Kong Index)to evaluate severity of dyspeptic symptoms. Symptom improvement is then determined.

Intervention(s) in this Clinical Trial

• Drug: lansoprazole
  • lansoprazole, 30mg, once daily for 14 days
• Drug: mosapride
  • mosapride, 5mg, thrice daily for 14 days

Arms, Groups and Cohorts in this Clinical Trial

• Experimental: 1
  • Treatment with lansoprazole (30mg)once daily for 14 days
• Active Comparator: 2
  • Treatment with mosapride (5mg)thrice daily for 14 days

Primary Measures

• Improvement of dyspeptic symptoms as evaluated by validated questionnaire
  • Time Frame: After 2-week treatment of lansoprazole or mosapride
    Safety Issue?: No

Inclusion Criteria:

• aged more than 20 years old
• diagnosis of functional dyspepsia by fulfilling Rome-III criteria
• outpatient

Exclusion Criteria:

• aged less than 20 years
• organic lesions including ulcers, tumors, bleeding, vasculopathy or esophagitis as demonstrated on upper endoscopy
• concurrent illness with malignancy, diabetes mellitus, liver cirrhosis, renal failure or porphyria
• diagnosis of organic disease for dyspeptic symptoms by treating physicians
• history of abdominal surgery
• concurrent user of aspirin and NSAID
• history of allergy or severe side effects to lansoprazole or mosapride
• pregnant or lactating women.

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 20 Years

Maximum Age for this Clinical Trial: 90 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Sponsor: Lotung Poh-Ai Hospital

Overall Clinical Trial Officials and Contacts

Yao-Chun Hsu, M.D. Principal Investigator Lotung Poh-Ai hospital, I-Lan County, Taiwan  

Overall Contact: Yao-Chun Hsu, M.D. 886-3-950-9579 holdenhsu@ntu.edu.tw

Information obtained from ClinicalTrials.gov on October 10, 2008

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00663897

Study ID Number: OMCP-97-007

ClinicalTrials.gov Identifier: NCT00663897

Health Authority: Taiwan: Department of Health

The homepage of ROME foundation, an non-for-profit organization dedicated to scientific research and education information of functional gastrointestinal disorders (FGIDs).